科学家发射REZENOPY,一种新的10毫克纳诺酮鼻腔喷雾剂,以防治阿片过量使用。 Scienture launches REZENOPY®, a new 10mg naloxone nasal spray, to combat opioid overdoses.

通过与Summit Biosciences和Kindeva Drug Delivery达成的协议,Scienture Holdings将通过商业推出REZENOPY®,这是一种强效的10mg纳洛鼻喷雾剂,用于阿片类药物过量服用. Scienture Holdings will commercially launch REZENOPY®, a potent 10mg naloxone nasal spray for opioid overdoses, through an agreement with Summit Biosciences and Kindeva Drug Delivery. 科学论者将处理销售和营销,而Kindeva将制造该药物。 Scienture will handle sales and marketing, while Kindeva will manufacture the drug. 美国食品和药物管理局在2024年批准了REZENOPY®,旨在帮助减少与阿片类药物相关的死亡. Approved by the FDA in 2024, REZENOPY® aims to aid in reducing opioid-related deaths.